Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2018

Open Access 01-12-2018 | Research

Intraoperative milrinone versus dobutamine in cardiac surgery patients: a retrospective cohort study on mortality

Authors: Dorthe Viemose Nielsen, Christian Torp-Pedersen, Regitze Kuhr Skals, Thomas A. Gerds, Zidryne Karaliunaite, Carl-Johan Jakobsen

Published in: Critical Care | Issue 1/2018

Login to get access

Abstract

Background

Several choices of inotropic therapy are available and used in relation to cardiac surgery. Comparisons are necessary to select optimal therapy. In Denmark, dobutamine and milrinone are the two inotropic agents most commonly used to treat post-bypass low cardiac output syndrome. This study compares all-cause mortality with these drugs.

Methods

In a retrospective observational study we investigated 10,700 consecutive patients undergoing cardiac surgery from 1 April 2006 to 31 December 2013 at Aarhus and Aalborg University Hospitals in the Central and Northern Denmark Region. Prospectively entered data in the Western Danish Heart Registry on intraoperative use of inotropes were used to identify 952 patients treated with milrinone, 418 patients treated with dobutamine, and 82 patients receiving a combination of the two inotropes. All-cause mortality among patients receiving dobutamine was compared to all-cause mortality among milrinone receivers.
Multiple logistic regression analyses including preoperative and intraoperative variables along with g-formula analyses were used to model 30-day and 1-year mortality risks. Reported were standardized mortality risk differences between the treatment groups.

Results

Among patients receiving intraoperative dobutamine, 18 (4.3%) died within 30 days and 49 (11.7%) within 1 year. Corresponding 30-day and 1-year mortality for milrinone receivers were 81 (8.5%) and 170 (17.9%). Risk of death within 30 days and 1 year was increased for intraoperative milrinone compared to dobutamine with a standardized risk difference of 4.06% (confidence interval (CI) 1.23; 6.89, p = 0.005) and 4.77% (CI 0.39; 9.15, p = 0.033), respectively. Sensitivity analyses including adjustment for milrinone preference, hemodynamic instability prior to cardiopulmonary bypass, and separate analyses on hospital level all confirmed a sign toward increased mortality among milrinone receivers.

Conclusions

Intraoperative use of milrinone in cardiac surgery may be associated with an increase in all-cause mortality compared to use of dobutamine.
Appendix
Available only for authorised users
Literature
1.
Algarni KD, Maganti M, Yau TM. Predictors of low cardiac output syndrome after isolated coronary artery bypass surgery: trends over 20 years. Ann Thorac Surg. 2011;92:1678–84.CrossRefPubMed
2.
Landoni G, Lomivorotov VV, Alvaro G, et al. Levosimendan for hemodynamic support after cardiac surgery. N Engl J Med. 2017;376:2021–31.CrossRefPubMed
3.
Lomivorotov VV, Efremov SM, Kirov MY, Fominskiy EV, Karaskov AM. Low-cardiac-output syndrome after cardiac surgery. J Cardiothorac Vasc Anesth. 2017;31:291–308.CrossRefPubMed
4.
Gillies M, Bellomo R, Doolan L, Buxton B. Bench-to-bedside review: Inotropic drug therapy after adult cardiac surgery—a systematic literature review. Crit Care. 2005;9:266–79.CrossRefPubMed
5.
Indolfi C, Piscione F, Perrone-Filardi P, et al. Inotropic stimulation by dobutamine increases left ventricular regional function at the expense of metabolism in hibernating myocardium. Am Heart J. 1996;132:542–9.CrossRefPubMed
6.
Schulz R, Rose J, Martin C, Brodde OE, Heusch G. Development of short-term myocardial hibernation. its limitation by the severity of ischemia and inotropic stimulation. Circulation. 1993;88:684–95.CrossRefPubMed
7.
Nielsen DV, Johnsen SP, Madsen M, Jakobsen CJ. Variation in use of peroperative inotropic support therapy in cardiac surgery: time for reflection? Acta Anaesthesiol Scand. 2011;55:352–8.CrossRefPubMed
8.
Hernandez AF, Li S, Dokholyan RS, O'Brien SM, Ferguson TB, Peterson ED. Variation in perioperative vasoactive therapy in cardiovascular surgical care: data from the society of thoracic surgeons. Am Heart J. 2009;158:47–52.CrossRefPubMed
9.
Mehta RH, Leimberger JD, van Diepen S, et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med. 2017;376:2032–42.CrossRefPubMed
10.
Feneck RO, Sherry KM, Withington PS. Oduro-Dominah A, European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. J Cardiothorac Vasc Anesth. 2001;15:306–15.CrossRefPubMed
11.
Carmona MJ, Martins LM, Vane MF, Longo BA, Paredes LS, Malbouisson LM. Comparison of the effects of dobutamine and milrinone on hemodynamic parameters and oxygen supply in patients undergoing cardiac surgery with low cardiac output after anesthetic induction. Rev Bras Anestesiol. 2010;60:237–46.PubMed
12.
Zangrillo A, Biondi-Zoccai G, Ponschab M, et al. Milrinone and mortality in adult cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth. 2012;26:70–7.CrossRefPubMed
13.
Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007;18:805–35.CrossRefPubMed
14.
Rasmussen LA, Botker HE, Jensen LO, et al. Quality assurance of the western denmark heart registry, a population-based healthcare register. Dan Med J. 2017;64:A5414.PubMed
15.
Schmidt M, Maeng M, Jakobsen CJ, et al. Existing data sources for clinical epidemiology: the Western Denmark Heart Registry. Clin Epidemiol. 2010;2:137–44.CrossRefPubMedPubMedCentral
16.
Nielsen DV, Hansen MK, Johnsen SP, Hansen M, Hindsholm K, Jakobsen CJ. Health outcomes with and without use of inotropic therapy in cardiac surgery: results of a propensity score-matched analysis. Anesthesiology. 2014;120:1098–108.CrossRefPubMed
17.
Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish civil registration system. A cohort of eight million persons. Dan Med Bull. 2006;53:441–9.PubMed
18.
Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999;16:9–13.CrossRefPubMed
19.
Roques F, Nashef SA, Michel P, et al. Risk factors and outcome in european cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg. 1999;15:816–22. Discussion 822–3CrossRefPubMed
20.
21.
Robins J. A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect. Math Model. 1986;7(9–12):1393–512.CrossRef
22.
Pearl J. Causal inference in statistics: an overview. Stat Sur. 2009;3:96–147.CrossRef
23.
24.
25.
Shahin J, Devarennes B, Tse CW, Amarica DA, Dial S. The relationship between inotrope exposure, six-hour postoperative physiological variables, hospital mortality and renal dysfunction in patients undergoing cardiac surgery. Crit Care. 2011;15:R162.CrossRefPubMedPubMedCentral
26.
Allen LA, Fonarow GC, Grau-Sepulveda MV, et al. Hospital variation in intravenous inotrope use for patients hospitalized with heart failure: insights from get with the guidelines. Circ Heart Fail. 2014;7:251–60.CrossRefPubMedPubMedCentral
27.
Writing committee members, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/american Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240–327.CrossRef
28.
Butterworth JF 4th, Legault C, Royster RL, Hammon JW Jr. Factors that predict the use of positive inotropic drug support after cardiac valve surgery. Anesth Analg. 1998;86:461–7.CrossRefPubMed
29.
Mebazaa A, Pitsis AA, Rudiger A, et al. Clinical review: Practical recommendations on the management of perioperative heart failure in cardiac surgery. Crit Care. 2010;14:201.CrossRefPubMedPubMedCentral
30.
Colucci WS, Wright RF, Jaski BE, Fifer MA, Braunwald E. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. Circulation. 1986;73:III175–83.PubMed
31.
Wright EM, Sherry KM. Clinical and haemodynamic effects of milrinone in the treatment of low cardiac output after cardiac surgery. Br J Anaesth. 1991;67:585–90.CrossRefPubMed
32.
Ushio M, Egi M, Wakabayashi J, et al. Impact of milrinone administration in adult cardiac surgery patients: updated meta-analysis. J Cardiothorac Vasc Anesth. 2016;30:1454–60.CrossRefPubMed
33.
Koster G, Bekema HJ, Wetterslev J, Gluud C, Keus F, van der Horst IC. Milrinone for cardiac dysfunction in critically ill adult patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med. 2016;42:1322–35.CrossRefPubMedPubMedCentral
34.
Greco T, Calabro MG, Covello RD, et al. A Bayesian network meta-analysis on the effect of inodilatory agents on mortality. Br J Anaesth. 2015;114:746–56.CrossRefPubMed
35.
Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541–7.CrossRefPubMed
36.
Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003;41:997–1003.CrossRefPubMed
37.
Feneck RO. Intravenous milrinone following cardiac surgery: I. Effects of bolus infusion followed by variable dose maintenance infusion. the European Milrinone Multicentre Trial Group. J Cardiothorac Vasc Anesth. 1992;6:554–62.CrossRefPubMed
38.
Ludmer PL, Wright RF, Arnold JM, Ganz P, Braunwald E, Colucci WS. Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique. Circulation. 1986;73:130–7.CrossRefPubMed
39.
Arbeus M, Axelsson B, Friberg O, Magnuson A, Bodin L, Hultman J. Milrinone increases flow in coronary artery bypass grafts after cardiopulmonary bypass: a prospective, randomized, double-blind, placebo-controlled study. J Cardiothorac Vasc Anesth. 2009;23:48–53.CrossRefPubMed
40.
Oztekin I, Yazici S, Oztekin DS, Goksel O, Issever H, Canik S. Effects of low-dose milrinone on weaning from cardiopulmonary bypass and after in patients with mitral stenosis and pulmonary hypertension. Yakugaku Zasshi. 2007;127:375–83.CrossRefPubMed
41.
Mekontso-Dessap A, Houel R, Soustelle C, Kirsch M, Thebert D, Loisance DY. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg. 2001;71:1428–32.CrossRefPubMed
42.
Weis F, Kilger E, Beiras-Fernandez A, et al. Association between vasopressor dependence and early outcome in patients after cardiac surgery. Anaesthesia. 2006;61:938–42.CrossRefPubMed
43.
DeWitt ES, Black KJ, Thiagarajan RR, et al. Effects of commonly used inotropes on myocardial function and oxygen consumption under constant ventricular loading conditions. J Appl Physiol. 2016;121:7–14.CrossRefPubMedPubMedCentral
44.
Eichhorn EJ, Konstam MA, Weiland DS, et al. Differential effects of milrinone and dobutamine on right ventricular preload, afterload and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1987;60:1329–33.CrossRefPubMed
45.
Parissis JT, Rafouli-Stergiou P, Stasinos V, Psarogiannakopoulos P, Mebazaa A. Inotropes in cardiac patients: update 2011. Curr Opin Crit Care. 2010;16:432–41.CrossRefPubMed
46.
Couture P, Denault AY, Pellerin M, Tardif JC. Milrinone enhances systolic, but not diastolic function during coronary artery bypass grafting surgery. Can J Anaesth. 2007;54:509–22.CrossRefPubMed
47.
Denault AY, Bussieres JS, Arellano R, et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Can J Anaesth. 2016;63:1140–53.CrossRefPubMed
Metadata
Title
Intraoperative milrinone versus dobutamine in cardiac surgery patients: a retrospective cohort study on mortality
Authors
Dorthe Viemose Nielsen
Christian Torp-Pedersen
Regitze Kuhr Skals
Thomas A. Gerds
Zidryne Karaliunaite
Carl-Johan Jakobsen
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2018
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-018-1969-1

Other articles of this Issue 1/2018

Critical Care 1/2018 Go to the issue

Research

Microcirculatory perfusion disturbances in septic shock: results from the ProCESS trial

Research

Serum suPAR and syndecan-4 levels predict severity of community-acquired pneumonia: a prospective, multi-centre study

Editorial

Thrombocytopenia in the ICU: disseminated intravascular coagulation and thrombotic microangiopathies—what intensivists need to know

Letter

Bundle of care taking into account time to improve long-term outcome after cardiac arrest

Research

Effect of postoperative goal-directed therapy in cancer patients undergoing high-risk surgery: a randomized clinical trial and meta-analysis

Research

Emergency Department disposition decisions and associated mortality and costs in ICU patients with suspected infection